Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0EMENQ
ADC Name
S-227928
Synonyms
S-227928; S 227928; S227928
   Click to Show/Hide
Organization
Novartis Institutes for Biomedical Research, Inc.
Drug Status
Phase 1/2
Indication
In total 3 Indication(s)
Acute myeloid leukaemia
Phase 2
Clinical Trial
Chronic myeloid leukemia
Phase 2
Clinical Trial
Myelodysplastic syndrome
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Undisclosed
Antigen Name
HLA class II histocompatibility antigen gamma chain (CD74)
  Antigen Info 
Payload Name
MIK665
  Payload Info 
Therapeutic Target
Induced myeloid leukemia cell differentiation protein (MCL1)
  Target Info 
Conjugate Type
Undisclosed